BCG vaccine
- Generic Name
- BCG vaccine
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 8VJE55B0VG
- Background
BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
- Associated Conditions
- Non-Invasive Bladder Urothelial Carcinoma, Recurrent Superficial Bladder Cancer, Tuberculosis (TB), Urothelial Carcinoma Recurrent, Carcinoma in situ of urinary bladder
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
- Conditions
- Non-Muscle-Invasive Bladder Cancer (NMIBC)
- Interventions
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 152
- Registration Number
- NCT06186414
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China
🇨🇳Renmin Hospital of Wuhan University, Wuhan, Hubei, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
BCG for Therapeutic Use Phase I Clinical Trial
- Conditions
- Non-muscular Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT06100653
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, China
Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Tamir Ben-Hur
- Target Recruit Count
- 60
- Registration Number
- NCT06078891
- Locations
- 🇮🇱
Department of Neurology, Hadassah medical Center, Jerusalem, Israel
First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b
- Conditions
- Healthy
- Interventions
- Biological: H107e/CAF®10b - full adjuvant doseBiological: H107eBiological: CAF®10bBiological: H107e/CAF®10bBiological: H107e/CAF®10b - low adjuvant doseBiological: i.m. placeboBiological: Full dose intranasal H107eBiological: Low dose intranasal H107eBiological: i.d. placeboBiological: Intranasal H107e
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 140
- Registration Number
- NCT06050356
- Locations
- 🇿🇦
Aurum Institute, Pretoria, Gauteng, South Africa
Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa
- Conditions
- TuberculosisHIV I Infection
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 276
- Registration Number
- NCT05947890
- Locations
- 🇿🇦
Cape Town - Khayelitsha, Cape Town, South Africa
🇿🇦Durban - Botha's Hill CRS, Durban, Kwa Zulu Natal, South Africa
🇿🇦Johannesburg - CHRU, Westdene, Gauteng,, South Africa
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
- Conditions
- Non-Muscle- Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT05943106
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1135
- Registration Number
- NCT05714202
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, China
🇨🇿Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia
🇰🇷Kangbuk Samsung Hospital, Seoul, Korea, Republic of
Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- National and Kapodistrian University of Athens
- Target Recruit Count
- 100
- Registration Number
- NCT05675176
- Locations
- 🇬🇷
Themistoklis Bellos, Marathon, Attica, Greece
Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study
- Conditions
- Non-muscle-invasive Bladder Cancer
- Interventions
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Al-Azhar University
- Target Recruit Count
- 280
- Registration Number
- NCT05626101
- Locations
- 🇪🇬
Mohamed Fawzy Salman, Cairo, Egypt
Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05592223
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.